Zimbabwe has rejected a major US healthcare agreement worth 367 million US dollars (£272m) spanning five years due to the United States' demand for sensitive data.
The decision came to light following a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official spokesperson later clarified that the United States was demanding access to health data for research and commercial purposes while was unwilling to guarantee the benefits from future treatments.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had provided over $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more dialogue to reach a agreement agreeable to both sides so the country's vital HIV programme can continue.
Broader Context
This rejection comes after a similar situation in Kenya, where a high court blocked a related deal with the US after concerns were raised about the safety of Kenyans' health data.
After resuming office last year, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had overseen assistance for the US government, but Trump argued its spending was "inefficient" and his administration was seeking government-to-government deals to boost openness and responsibility.
As per statements, 16 African countries have so far agreed to similar health pacts, representing over $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on HIV treatment via US-supported programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no equivalent assurance of benefiting from any medical innovations – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our nation would supply the raw materials for scientific discovery with no certainty that the end products would be available to our citizens should a future pandemic emerge."
National Interest and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral deals were undermining structures already set up through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This system is designed to guarantee that when a nation contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We are open to further dialogue with our American counterparts on how future collaboration could be arranged in a manner that respects the sovereignty and interests of each country."
Health Experts Reaction
Medical experts expressed it understood the government's concerns, but suggested that talks must proceed given that a large portion of the nation's HIV programmes depended on external financing.
"Where specific concerns arise, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," the group said.
This impasse highlights the complex challenges between receiving crucial foreign assistance and protecting national sovereignty in an ever more interconnected world.